<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38302946</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Acute and persistent symptoms of COVID-19 infection in school-aged children: a retrospective study from China.</ArticleTitle><Pagination><StartPage>344</StartPage><MedlinePgn>344</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">344</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-17822-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">The long-term sequelae of Coronavirus disease 2019 (COVID-19) in children are unclear. We investigated COVID-19 symptoms in school-aged children to determine their impact on patients and their families.</AbstractText><AbstractText Label="METHODS">This cross-sectional study, conducted on February 25-28, 2023, selected a representative kindergarten and 9-year school from Shenzhen, China. There were randomly two classes each for the 12 grades from kindergarten to junior high school. The school-aged children were aged 3-16 years. Literate parents completed an online questionnaire related to their children's COVID-19 symptoms since December 1, 2022. Descriptive statistics were computed as necessary. Univariate and multivariable linear regression analyses were performed, and variables with a p-value&#x2009;&lt;&#x2009;0.05 were considered to have a significant association with the subjective feeling scores for COVID-19 infection.</AbstractText><AbstractText Label="RESULTS">We included 936 school-aged children, with a COVID-19 infection rate of 68.5%. The prevalence of LC 28 (illness with symptoms lasting for 28 days) was 3.4%. During acute infection, the median number of the 641 children's symptoms was 3.0 (IQR: 1.0-5.0) and the median score of subjective feelings was 15.0 (IQR: 11.0-24.5). The top three symptoms were fever, cough/expectoration, and rhinobyon. Age of 13-16 years (adjusted beta: 3.60, 95% CI: 0.32-6.88) and comorbidities (adjusted beta: 3.47, 95% CI: 1.20-5.73) were independently associated with higher subjective feelings (p&#x2009;&lt;&#x2009;0.05). The top three characteristics associated with LC 28 were alopecia (33.3%, 5/15), cognitive dysfunction (29.2%, 7/24), and emotional problem (28.6%, 6/21).</AbstractText><AbstractText Label="CONCLUSIONS">Children with COVID-19 have a short duration of symptoms and milder symptoms, so they can self-medicate to minimize hospital crowding. Children with basic diseases require prompt attention. Although LC 28 is uncommon in children, mental and psychological problems after COVID-19 recovery should not be ignored.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Honglin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Communicable Diseases Control and Prevention, Shenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, 518055, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Disease Control Division, Public Health Service Center, Bao'an District, 518103, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Xiuxian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Disease Control Division, Public Health Service Center, Bao'an District, 518103, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Rijing</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, 510515, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Linxiang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunization Planning, Luohu District Center for Disease Control and Prevention, 518020, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology, 518112, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Communicable Diseases Control and Prevention, Shenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, 518055, Shenzhen, China. zhangzhen@wjw.sz.gov.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Qiuying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Communicable Diseases Control and Prevention, Shenzhen Center for Disease Control and Prevention, 8 Longyuan Rd, 518055, Shenzhen, China. sandylv1980@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JCYJ202103241154-11030</GrantID><Agency>The Key Project of Shenzhen Science and Technology Innovation Commission</Agency><Country/></Grant><Grant><GrantID>JCYJ202103241154-11030</GrantID><Agency>The Key Project of Shenzhen Science and Technology Innovation Commission</Agency><Country/></Grant><Grant><GrantID>JCYJ202103241154-11030</GrantID><Agency>The Key Project of Shenzhen Science and Technology Innovation Commission</Agency><Country/></Grant><Grant><GrantID>SZXK064</GrantID><Agency>Shenzhen Key Medical Discipline Construction Fund</Agency><Country/></Grant><Grant><GrantID>SZXK064</GrantID><Agency>Shenzhen Key Medical Discipline Construction Fund</Agency><Country/></Grant><Grant><GrantID>SZXK064</GrantID><Agency>Shenzhen Key Medical Discipline Construction Fund</Agency><Country/></Grant><Grant><GrantID>SZSM202011008</GrantID><Agency>Shenzhen San-Ming Project of Medicine in Shenzhen</Agency><Country/></Grant><Grant><GrantID>SZSM202011008</GrantID><Agency>Shenzhen San-Ming Project of Medicine in Shenzhen</Agency><Country/></Grant><Grant><GrantID>SZSM202011008</GrantID><Agency>Shenzhen San-Ming Project of Medicine in Shenzhen</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 infection</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-Cov-2</Keyword><Keyword MajorTopicYN="N">School-aged children</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38302946</ArticleId><ArticleId IdType="pmc">PMC10835839</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-17822-5</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-17822-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Listings of WHO&#x2019;s response to COVID-19. Available at: Accessed on: 11 February 2022.</Citation></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/ Accessed on: March 13, 2023.</Citation></Reference><Reference><Citation>Asakawa T. Focusing on development of novel sampling approaches and alternative therapies for COVID-19: are they still useful in an era after the pandemic? Biosci Trends. 2022;16(6):386&#x2013;8. doi: 10.5582/bst.2022.01506.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2022.01506</ArticleId><ArticleId IdType="pubmed">36504074</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;15. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 rapid . Evidence reviews 2 and 3: prevalence. London: National Institute for Health and Care Excellence (NICE); 2020. Guideline: managing the long-term effects of COVID-19 (NG188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555766</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26(7):1037&#x2013;40. doi: 10.1038/s41591-020-0916-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0916-2</ArticleId><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;31. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N et al. Characterising long COVID: a living systematic review. BMJ Glob Health, 2021; 6(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnood SA, Shafran R, Bennett SD, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect. 2022;84(2):158&#x2013;70. doi: 10.1016/j.jinf.2021.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.11.011</ArticleId><ArticleId IdType="pmc">PMC8604800</ArticleId><ArticleId IdType="pubmed">34813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Sigfrid L, Warner JO. Setting priorities to address research gaps in long-term COVID-19 outcomes in children. JAMA Pediatr. 2021;175(11):1095&#x2013;6. doi: 10.1001/jamapediatrics.2021.2281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.2281</ArticleId><ArticleId IdType="pubmed">34338711</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Zhao S, Chong KC, et al. Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen. Lancet Infect Dis. 2023;23(4):403&#x2013;4. doi: 10.1016/S1473-3099(23)00112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00112-3</ArticleId><ArticleId IdType="pubmed">36803917</ArticleId></ArticleIdList></Reference><Reference><Citation>Xinhua. China focus: COVID-19 response further optimized with 10 new measures. 2022.</Citation></Reference><Reference><Citation>WHO. TAG-VE statement on the meeting of 3 January on the COVID-19 situation in China. 2023.</Citation></Reference><Reference><Citation>Choi SH, Choi JH, Lee JK, et al. Clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea. J Korean Med Sci. 2023;38(9):e65. doi: 10.3346/jkms.2023.38.e65.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e65</ArticleId><ArticleId IdType="pmc">PMC9988433</ArticleId><ArticleId IdType="pubmed">36880106</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, I KS, Eliasen EH, et al. Clinical characteristics of the Omicron variant - results from a nationwide symptoms Survey in the Faroe Islands. Int J Infect Dis. 2022;122:636&#x2013;43. doi: 10.1016/j.ijid.2022.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.07.005</ArticleId><ArticleId IdType="pmc">PMC9303132</ArticleId><ArticleId IdType="pubmed">35811082</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWitt ME, Tjaden AH, Herrington D, et al. COVID-19 symptoms by variant period in the North Carolina COVID-19 community research partnership, North Carolina, USA. Emerg Infect Dis. 2023;29(1):207&#x2013;11. doi: 10.3201/eid2901.221111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2901.221111</ArticleId><ArticleId IdType="pmc">PMC9796200</ArticleId><ArticleId IdType="pubmed">36573634</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618&#x2013;24. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha J, Meng C, Sun J, et al. Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. J Infect Public Heal. 2023;16(3):422&#x2013;9. doi: 10.1016/j.jiph.2023.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.01.013</ArticleId><ArticleId IdType="pmc">PMC9854235</ArticleId><ArticleId IdType="pubmed">36731245</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc. 2021;5(10):708&#x2013;18. doi: 10.1016/S2352-4642(21)00198-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00198-X</ArticleId><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Dargham SR, Loka S et al. Coronavirus disease 2019 disease severity in children infected with the Omicron variant. Clin Infect Dis 2022 2022-08-24;75(1):e361&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047187</ArticleId><ArticleId IdType="pubmed">35404391</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Roy P et al. Long COVID following Omicron wave in Eastern India-A retrospective cohort study. J Med Virol 2023 2023-01-01;95(1):e28214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9874641</ArticleId><ArticleId IdType="pubmed">36224705</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasmieh SA, Robertson MM, Teasdale CA et al. The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June-July 2022. Prev Med 2023 2023-04-01;169:107461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9940463</ArticleId><ArticleId IdType="pubmed">36813250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathirvel N. Post COVID-19 pandemic mental health challenges. Asian J Psychiatr 2020 2020-10-01;53:102430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507979</ArticleId><ArticleId IdType="pubmed">33264840</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE et al. Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. medRxiv 2022 2022-07-22.</Citation></Reference><Reference><Citation>Cysique LA et al. Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study. Preprint at medRxiv 10.1101/2022.06.07.22276020 (2022).</Citation></Reference><Reference><Citation>Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health 2020 2020-12-01;9:100163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581383</ArticleId><ArticleId IdType="pubmed">33111132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, De Lorenzo R, Conte C et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun 2020 2020-10-01;89:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere JJ, Serafini RA, Pryce KD et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med 2022 2022-09-28;14(664):q3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>